Agios Reports Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Agios Pharma (AGIO) PT Raised to $80 at Credit Suisse; 'Platform opportunities beyond IDH'
February 15, 2018 8:59 AM ESTCredit Suisse raised its price target on Agios Pharma (NASDAQ: AGIO) to $80.00 (from $66.00) while maintaining a Outperform rating.
... MoreAgios Pharma (AGIO) PT Raised to $86 at Needham & Company; 'Continued Execution'
February 14, 2018 12:48 PM ESTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $86.00 (from $72.00) while maintaining a Buy rating.
Analyst Chad Messer commented, " Agios made broad progress across its growing pipeline in 2017 and we expect another busy year with their 2nd drug launch and... More
Agios Pharma (AGIO) Misses Q4 EPS by 15c
February 14, 2018 7:08 AM ESTAgios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.81), $0.15 worse than the analyst estimate of ($1.66). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $13.34 million.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
... More